The facility produces the viral vector-based active pharmaceutical ingredient in Adstiladrin, the only non-replicating gene therapy for high-risk non-muscle invasive bladder cancer that has been approved by the FDA. FinVector is part of the international company Ferring Ventures, and since 2014 the Ferring Group has invested over EUR 600 million in the development of this treatment, of which more than half has been in Finland and Kuopio.

Related article

Pushing the boundaries of gene therapy

FinVector has emerged as a pioneer in the manufacturing of viral-based gene therapy. The company is this year’s BioFinland Award winner and NLS asked Matthias Krieger, Managing Director, about milestones, gene therapy, and not least, the importance of teamwork.


“The development of our Finport facility, a state-of-the-art manufacturing site [four-story, 25,000m2], is a key highlight. It not only creates high-quality jobs and brings skilled talent and taxpayer money to Kuopio, but also positions the city as a hub for health tech innovation and a growing ecosystem in Finland,” says Matthias Krieger, Managing Director, FinVector.

Illustration of FinPort

A place where science gives hope

FinVector is one of the largest private-sector employers in and around Kuopio, having more than doubled its staff to around 500 in the past 30 months.

“Looking back ten years to when Ferring Group and Trizell acquired FinVector, the progress we’ve made could not have been predicted. “Teamwork makes the dream work” is not just a saying here, it’s a principle that has guided us to where we are today. While it’s difficult to predict the exact trajectory of innovation over the next decade, our commitment to manufacturing cutting-edge precision medicine for patients and our partnership with Ferring remains steadfast. Our vision is to be a place where science gives hope. We are focused on pushing the boundaries of what’s possible in gene therapy, and I’m excited to see where this journey takes us in the future,” says Krieger.